Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy [Original Articles]

Conclusions— The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

http://circheartfailure.ahajournals.org/cgi/content/short/9/9/e003212?rss=1

Source: Circulation: Heart Failure - September 11, 2016 Category: Cardiology Authors: Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., McMurray, J. J. V., on behalf of the PARADIGM-HF Investigators and Committees* Tags: Clinical Studies, Heart Failure, Treatment, Mortality/Survival Original Articles Source Type: research